In the News
-
Pfizer and Protalix BioTherapeutics Announce Submission of taliglucerase alfa for European Marketing Authorization for the Treatment of Gaucher Disease
29 November 2010
New York, NY/Carmiel, Israel, November 29, 2010 – Pfizer Inc. (NYSE: PFE) and Protalix BioTherapeutics, Inc. (NYSE-AMEX: PLX, TASE:PLX)today announced...
Read more....
-
Head-to-Head Data Demonstrates Efficacy of VPRIVA
08 November 2010
Cambridge, MA, US – November 4, 2010 – Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, today presented positive n...
Read more....
-
Positive Data from taliglucerase alfa Switchover Trial
08 November 2010
Protalix BioTherapeutics, Inc. announced positive preliminary data from the first 15 patients that completed the Company's nine month, worldwide, mult...
Read more....